Indeed, the number of overall CD8+ T cells and tumor-reactive CD8+ T cells making granzyme B were significantly higher in the combination treatment group compared to the other treatment groups (Fig. 8f, g), indicating that the infiltration of tumor-killing CD8+ T cells could be enhanced by the combined treatment. The gene discussed is GZMB; the disease is neoplasm.